A CME Symposium during the 2024 American Heart Association (AHA) Annual Scientific Sessions in Chicago, Illinois.

AGENDA

6:00 pm           Introduction

6:10 pm           Clinical Impact of Suboptimal RAASi Therapy Following an Episode of

                        Hyperkalemia

                        Mark Petrie, MD

6:30 pm           Overcoming Barriers to Guideline-Mandated RAASi Use:  Focus on Hyperkalemia and Potassium Binders

Mikhail Kosiborod, MD

6:50 pm           Fine-Tuning the Management of HF Patients with Elevated Potassium:  Case Presentation and Discussion

                        Case Presenter:  Shelley Zieroth, MD, FRCP(C)

Panelists:  David Cherney, MD CM, PhD, FRCP(C); Mikhail Kosiborod, MD;

      Mark Petrie, MD

7:10 pm           Question and Answer

EDUCATIONAL OBJECTIVES

• Describe the relationship between suboptimal RAASi therapy and poor cardiorenal outcomes
• Explain clinical data with, and demonstrate prudent use of novel potassium binders
• Identify patients who would benefit from anti-hyperkalemia medications

Educational Grant
Voxmedia International gratefully acknowledges the educational grant
provided by AstraZeneca Pharmaceuticals.

CHAIR

Mikhail Kosiborod, MD

Vice President of Research

Saint Luke’s Health System

Professor of Medicine

University of Missouri-Kansas City

Kansas City, Missouri

FACULTY

David Cherney, MD CM, PhD, FRCP(C)

Professor of Medicine, University of Toronto

Clinician Scientist, Division of Nephrology, UHN

Director, Renal Physiology Laboratory, UHN

Senior Scientist, Toronto General Hospital Research Institute

Toronto, Ontario, Canada

Mark Petrie, MD

Professor of Cardiology

Honorary Consultant

School of Cardiovascular & Metabolic Health

University of Glasgow

Glasgow, Scotland

Shelley Zieroth, MD, FRCP(C)

Professor of Medicine

Max Rady College of Medicine

University of Manitoba

Winnipeg, Manitoba, Canada